Therapy is aimed at decreasing pathogenic IgA production and immune complex formation as well as managing the effects of existing nephron loss.
Julia Griffith, PharmD
Advertisement
Articles by Julia Griffith, PharmD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Drug Topics
1
PBM Underpayment Persists as Cost-Plus Brings New Strain | NCPA 2026
2
FAQ: Scaling Pharmacy Services Through GLP-1 Care | NCPA 2026
3
PBM Network Terminations Bring Risks Beyond Lost Contracts | NCPA 2026
4
FDA Approves Brytly for OTC Eye Redness Relief
5